Company profile: PanThera CryoSolutions
1.1 - Company Overview
Company description
- Provider of cryopreservation solutions for cells, tissues, and organs, featuring IRIs that control ice crystal size and growth to improve cell recovery/quality and reduce warming damage; IRIs mitigate toxicity of conventional cryoprotective agents to enable higher sub-zero storage temperatures, with GMP-compliant manufacturing and less costly storage/transport, restricting liquid nitrogen use in some cell treatment applications.
Products and services
- Cryopreservation Solutions: Evidence-based systems incorporating IRIs to mitigate toxicity of conventional cryoprotective agents, permit higher sub-zero storage temperatures, reduce liquid nitrogen dependence, and enable less expensive storage and transportation
- Ice Recrystallization Inhibitors (IRIs): Scientifically developed components controlling ice crystal size and growth during cryopreservation, enhancing cell recovery and quality, and reducing warming-event damage in cells, tissues, and organs
- GMP-Compliant Product Manufacturing: GMP-compliant process constructing cryopreservation products for cells, tissues, and organs, ensuring high safety, efficacy, and quality standards throughout production.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PanThera CryoSolutions
Immunophotonics
HQ: United States
Website
- Description: Provider of immunotherapy-based cancer treatments, including IP-001, a proprietary glycan polymer that stimulates immune responses against cancer and infectious diseases by acting as an antigen depot and immune activator; and an Abscopalizing Technique involving IP-001 injection with tumor ablation or radiation to induce a systemic immune response against cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunophotonics company profile →
Ingenium Pharmaceuticals
HQ: Germany
Website
- Description: Provider of drug development, operating as a subsidiary of Probiodrug AG, an integrated drug development company; founded in 1998 as a spin-off from the German Human Genome Project.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ingenium Pharmaceuticals company profile →
Univercells
HQ: Belgium
Website
- Description: Provider of end-to-end, high-density, low-cost biomanufacturing solutions, including the NevoLine vaccine platform (incl. inactivated polio vaccine), scale-X single-use bioreactors, Exothera viral vector CDMO, custom bioproduction hubs with preclinical to commercial GMP capabilities, turnkey advisory for local site design/operation/regulatory compliance, and Ntensify RNA production in mobile labs; engineered to cut investments >75% and cost of goods up to 90%.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Univercells company profile →
Lucy Therapeutics
HQ: United States
Website
- Description: Provider of mitochondrial-based small molecule therapies targeting mitochondrial dysfunction to treat complex diseases with a focus on neurological disorders; diagnostic biomarkers for disease diagnosis and progression monitoring; lead programs in Parkinson's disease and Rett syndrome; and early discovery efforts for undisclosed targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lucy Therapeutics company profile →
Lightspeed Genomics
HQ: United States
Website
- Description: Provider of a high-speed DNA sequencing platform enabling faster, lower-cost human genome sequencing. The technology supports innovation in basic research, drug development, and medical diagnostics, driving advances in healthcare.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lightspeed Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PanThera CryoSolutions
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PanThera CryoSolutions
2.2 - Growth funds investing in similar companies to PanThera CryoSolutions
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PanThera CryoSolutions
4.2 - Public trading comparable groups for PanThera CryoSolutions
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →